Clinical indications for combined MII-pH testing include

- To quantify and characterize gastroesophageal reflux in patients who have had a minimal or lack of response to acid-suppressive therapy with a proton pump inhibitor (PPI) and who have normal endoscopic findings.

- To evaluate patients with atypical gastroesophageal reflux symptoms

- To evaluate patients with reflux symptoms and achlorhydria (i.e., atrophic gastritis)

- To evaluate patients with reflux symptoms after surgical gastrectomy

- To evaluate patients with primary postprandial symptoms

- To evaluate patients with reflux symptoms and frequent meal ingestion (i.e., infants)